-- Vitamin B1 Tablets: as a supplement to prevent certain illness, such
as beriberi and dyspepsia.
"We are very excited about these nine new drugs, which complement our product portfolio nicely. We estimate that revenue from them will reach USD $5.0 million in 2009," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "As part of our strategy, we will continue to look for opportunities to add suitable pharmaceuticals to our portfolio to enhance and expand our product line."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Company Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by the
use of forward- looking terminology such as "believe," "expect," "may,"
"will," "should," "project," "plan," "seek," "intend," or "anticipate" or
the negative thereof or comparable terminology. Such statements typically
involve risks and uncertainties and may include financial projections or
information regarding our future plans, objectives or performance. Actual
results could differ materially from the expectations reflected in such
|SOURCE China Sky One Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved